Table 1.
HPV specific IgG and IgA antibody titers in sera of women immunized with Gardasil.
| Name | Source | Immunization Status |
End-Point Titer by ELISA |
|
|---|---|---|---|---|
| IgG | IgA | |||
| WH 102 | UAB | Post | 64,000 | 8,000 |
|
|
|
|||
| WH 113 | Post | 32,000 | 600 | |
|
| ||||
| Control | Volunteer | None | — | — |
|
| ||||
| 4851 | Merck & Co., Inc. |
Pre, Day 1 | 4,000 | 1,900 |
|
|
|
|||
| 4861 | Post, Month 7 | 64,000 | 2,400 | |
|
|
|
|||
| 4871 | Pre, Day 1 | 4,000 | 1,600 | |
|
|
|
|||
| 4881 | Post, Month 7 | 80,000 | 3,200 | |
|
|
|
|||
| 4891 | Pre, Day 1 | 2,000 | 2,200 | |
|
|
|
|||
| 4901 | Post, Month 7 | 60,000 | 4,800 | |
|
|
|
|||
| 4911 | Pre, Day 1 | 1,000 | 800 | |
|
|
|
|||
| 4921 | Post, Month 7 | 64,000 | 12,800 | |
End-point titers of Gardasil-specific IgG and IgA were determined by ELISA in 16 immune sera received from UAB (see also Table S1) and 4 pairs of pre- and post- immune sera provided by Merck & Co., Inc. Only two sera (WH102, WH113) from UAB with the highest antibody titers were used in this study.